Table 2 Predictors of HBeAg status among patients with HIV-HBV co-infection: Univariate analyses

Sex

0. 59

female

2 (66. 67%)

1 (33. 33%)

1. 00

male

42(50. 60%)

41 (49. 40%)

1. 95

0. 17-22. 37

Age

0. 16

< = 42 years

18 (43. 9%)

23 (56. 1%)

1. 00

> 42 years

26 (59. 09%)

18 (40. 91%)

0. 54

0. 22-1. 28

CD4

< 350 cels/μ1

12 (46. 15%)

14 (53. 85%)

1. 00

0. 54

> 350 cels/μ1

32 (53. 33%)

28 (46. 67%)

0. 75

0. 29-1. 88

Use of ARV

0. 18

no

1(20%)

4 (80%)

1. 00

yes

43 (53. 09%)

38 (46. 91%)

0. 22

0. 02-2. 06

HBV Genotype

0. 68

A

5 (23. 8%)

16 (78. 1%)

0. 58

0. 1-3. 2

Non-A

2 (19. 3%)

11 (84. 6)

1. 00

Previous use of LAM

0. 64

no

3 (42. 8%)

4 (57. 1%)

1. 00

yes

41(51. 9%)

38 (48. 10%)

0. 69

0. 14-3. 31

Previous use of TDF

no

22 (57. 8%)

16 (42. 11%)

1. 00

0. 26

yes

22 (45. 8%)

26 (54. 1%)

1. 62

0. 68-3. 83

Time of TDF use > 12 months

0. 73

no

6 (50%)

6 (50%)

1. 00

yes

16 (44. 4%)

20 (55. 5%)

1. 25

0. 33-4. 62

HBV-DNA

< 0. 001

< 60 UI/mL

34(40. 9%)

15(18%)

1. 00

> 60 UI/mL

08(9. 6%)

26(31. 3%)

21. 52

4. 58-100. 98

ALT Level

0. 002

Normal

39(46. 9%)

24(28. 9%)

1. 00

> 1. 5 × ULN

4(4. 8%)

16(19. 2)

6. 66

1. 99-22. 28

Compliance to therapy

0. 26

yes

41 (53. 25%)

36 (46. 75%)

1. 00

no

3 (33. 3%)

6 (66. 6%)

2. 27

0. 53-9. 77